Beam Therapeutics Inc. (BEAM) News

Beam Therapeutics Inc. (BEAM): $96.57

1.10 (+1.15%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BEAM to Watchlist
Sign Up

Industry: Biotech


Ranked

of 505

in industry

Filter BEAM News Items

BEAM News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

BEAM News Highlights

  • BEAM's 30 day story count now stands at 4.
  • Over the past 16 days, the trend for BEAM's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about BEAM are GENE, ALX and ALXO.

Latest BEAM News From Around the Web

Below are the latest news stories about Beam Therapeutics Inc that investors may wish to consider to help them evaluate BEAM as an investment opportunity.

7 Gene Editing Stocks Promising to Change our DNA

Gene editing stocks will take off as the underlying tech moves from fiction to fact and companies put their products on the market.

Chris Markoch on InvestorPlace | September 15, 2021

Could a Recent Gene Editing Breakthrough Make This Cathie Wood Stock a Buy?

One of the pioneers of CRISPR gene editing research, Feng Zhang, recently achieved a breakthrough in how CRISPR therapies can be delivered to cells. In this Motley Fool Live video recorded on Sept. 1, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss Zhang's achievement and what it could mean for Beam.

Yahoo | September 12, 2021

Beam Therapeutics to Participate in the 2021 Wells Fargo Virtual Healthcare Conference

CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the 2021 Wells Fargo Virtual Healthcare Conference on Friday, Sept. 10, 2021 at 9:20 a.m. ET. The live webcast will be available in the investor section of the company's website at www.beamtx.com. The webcast will be archi

Yahoo | September 8, 2021

Forget About the Genomic Revolution, the Proteomic Revolution Is Coming

Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing.

Luke Lango on InvestorPlace | September 3, 2021

The 3 Best Biotech Stocks to Buy Right Now

Investing in biotech companies is hard. Shareholders are often subject to wild price swings based on results that may not translate to future studies. ALX Oncology (NASDAQ: ALXO), Vertex Pharmaceuticals (NASDAQ: VRTX), and Beam Therapeutics (NASDAQ: BEAM) are at different stages of the company lifecycle.

Yahoo | August 27, 2021

3 Stocks to Avoid if Cathie Wood's ARK ETF Falls

If you haven't heard of Michael Burry, you might know of him. Through options, he is betting on Cathie Wood's flagship ARK Innovation ETF (NYSEMKT: ARKK) to drop. Three holdings of Wood's fund I think may be especially at risk are Tesla (NASDAQ: TSLA), Coinbase (NASDAQ: COIN), and Beam Therapeutics (NASDAQ: BEAM).

Yahoo | August 21, 2021

How Much Of Beam Therapeutics Inc. (NASDAQ:BEAM) Do Insiders Own?

The big shareholder groups in Beam Therapeutics Inc. ( NASDAQ:BEAM ) have power over the company. Institutions will...

Yahoo | August 14, 2021

Company News for Aug 11, 2021

Companies In The News Are: VSH, SYY, NOVT, BEAM

Yahoo | August 11, 2021

Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates

Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of -63.79% and -99.98%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 10, 2021

Beam Therapeutics Provides Business and Pipeline Updates and Reports Second Quarter 2021 Financial Results

Company On-track to Submit First IND for BEAM-101 in the Second Half of 2021 Continued Progress Across Base Editing Portfolio, Including Initiation of IND-Enabling Studies for BEAM-201 CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported recent business and pipeline updates, as well as second quarter 2021 financial results. “We have made meaningful progress in

Yahoo | August 10, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7122 seconds.